AnaptysBio

ANAB · Nasdaq · United States

Share price · ANAB

$47.06-11.93 (-20.22%) 3M

close as of 2026-11-18 · 24h delayed · vol 567K (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 21 Oct 2026+5.5%
  2. 20 Oct 2026-7.7%
  3. 20 Jul 2026-13.3%

    Nothing announced by ANAB that day or the session before.

  4. 15 Jul 2026-10.7%
  5. 14 Jul 2026-10.5%

    Nothing announced by ANAB that day or the session before.

  6. 27 Apr 2026+13.1%
  7. 24 Apr 2026+14.8%
  8. 20 Apr 2026+13.2%
  9. 6 Apr 2026+8.2%
  10. 27 Mar 2026-11.7%

Share of unusual movement by asset

For each asset, the share of ANAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Imsidolimab
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—46%
Sessions with no dated event—54%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-36 receptorMonoclonal antibody
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

12 December 2026FDA action dateimsidolimabImsidolimab BLA PDUFA target action date
US, FDA · Vanda Pharmaceuticals · Source ↗

Recent

25 February 2026Filing acceptedimsidolimabFDA accepts imsidolimab BLA
US, FDA · Vanda Pharmaceuticals · Source ↗
15 December 2025Filing submittedImsidolimabBLA submitted to FDA for imsidolimab in GPP
US, FDA · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$30M—$135M+ $18M short-term inv.—-$9.5M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$26M$34M$248M+ $38M short-term inv.$53M-$26M operating cash flowreport ↗
2025-Q3$76M$31M$110M+ $139M short-term inv.—-$27M operating cash flowreport ↗
2025-Q2$22M$38M$44M+ $221M short-term inv.$39M-$40M operating cash flowreport ↗
2025-Q1$28M$41M$99M+ $241M short-term inv.$39M-$11M operating cash flowreport ↗
2024-Q3$30M$42M$192M+ $239M short-term inv.$33M-$10M operating cash flowreport ↗
2024-Q2$11M$42M$72M+ $279M short-term inv.$47M-$21M operating cash flowreport ↗
2024-Q1$7.2M$37M$54M+ $301M short-term inv.$44M-$37M operating cash flowreport ↗
2023-Q3$3.3M$31M$26M+ $387M short-term inv.$37M-$36M operating cash flowreport ↗
2023-Q2$3.5M$33M$35M+ $394M short-term inv.$40M-$25M operating cash flowreport ↗
2023-Q1$1.4M$35M$95M+ $337M short-term inv.$44M-$25M operating cash flowreport ↗
2022-Q3$1.3M$22M$59M+ $384M short-term inv.$34M-$18M operating cash flowreport ↗
2022-Q2$1.2M$21M$72M+ $370M short-term inv.$33M-$24M operating cash flowreport ↗
2022-Q1$1.0M$23M$166M+ $339M short-term inv.$36M-$21M operating cash flowreport ↗
2021-Q3$21M$22M$336M+ $38M short-term inv.$6.7M-$7.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$235M—$238M+ $73M short-term inv.$3.3M$20M operating cash flowreport ↗

AnaptysBio reported full-year 2025 collaboration revenue of $234.6M, up 157.0% YoY from $91.28M, driven largely by Jemperli royalties and a $75M commercial sales milestone from GSK. R&D expenses were $136.0M for the year, down from $163.8M, and the company ended 2025 with cash and investments of $311.6M, including cash and equivalents of $238.2M. The company recorded a full-year net loss of $13.2M, or $0.46 per share.

The planned spin-off of its biopharma operations into First Tracks Biotherapeutics remains on track for Q2 2026, potentially as early as late-April. ANB033’s Phase 1b trial in celiac disease is ongoing and a cohort was initiated in eosinophilic esophagitis, with top-line data anticipated in Q4 2026 and 2027, respectively. GSK reported Jemperli Q4 2025 sales of $343M, up >13% quarter-over-quarter, implying a ~$1.4B annualized run rate, and Anaptys expects to achieve >$390M in annualized Jemperli royalties payable at GSK’s peak sales guidance of >$2.7B as early as 2029.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$91M—$123M+ $262M short-term inv.$36M-$135M operating cash flowreport ↗
2023-FY$17M—$36M+ $355M short-term inv.$41M-$121M operating cash flowreport ↗
2022-FY$10M$89M$71M+ $370M short-term inv.$32M-$74M operating cash flowreport ↗
2021-FY$63M$99M$496M+ $52M short-term inv.$14M-$46M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($17.2M), 42 sales ($9.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% ownerOpen-market purchase138,093$46.54$6.4MForm 4
2026-11-17EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% ownerOpen-market purchase152,367$45.66$7.0MForm 4
2026-11-16EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% ownerOpen-market purchase84,120$45.66$3.8MForm 4
2026-10-01RENTON HOLLINGS · directorOption exercise5,000$18.03$90KForm 4
2026-10-01RENTON HOLLINGS · directorOpen-market sale5,000$49.87$249KForm 4
2026-10-01RENTON HOLLINGS · directorOption exercise (derivative)5,000——Form 4
2026-09-15Orwin John A · directorOption exercise1,300——Form 4
2026-09-15Orwin John A · directorOption exercise (derivative)1,300——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 206 reporting institutions held 28.2M shares ($1.5B, 95.0% of shares outstanding).

#InstitutionSharesValue
1EcoR1 Capital, LLC7,880,094$437.0M
2BlackRock, Inc.1,681,380$93.2M
3TANG CAPITAL MANAGEMENT LLC1,330,879$73.8M
4MORGAN STANLEY993,905$55.1M
5STATE STREET CORP992,445$55.0M
6Affinity Asset Advisors, LLC940,000$52.1M
7VANGUARD CAPITAL MANAGEMENT LLC853,151$47.3M
8Palo Alto Investors LP638,161$35.4M
9683 Capital Management, LLC625,000$34.7M
10D. E. Shaw & Co., Inc.579,296$32.1M
11First Light Asset Management, LLC565,431$31.4M
12Sanofi821,917$30.4M
13GEODE CAPITAL MANAGEMENT, LLC520,241$28.9M
14VANGUARD PORTFOLIO MANAGEMENT LLC519,870$28.8M
15BANK OF AMERICA CORP /DE/501,086$27.8M